Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Elvitegravir

FDA-approved product (tablet, oral), marketed as Vitekta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Elvitegravir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Elvitegravir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Elvitegravir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

    NCT02220868 · start 2014-07

    Registered record
    Registry ID
    NCT02220868
    Conditions
    Hepatitis C Infection; HIV Infection
    Interventions
    Sofosbuvir, Ribavirin, and Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2015-09
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Infection; HIV Infection
    InterventionSofosbuvir, Ribavirin, and Stribild
    PhasePhase 4
    Registry statusCompleted

  • Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

    NCT02016924 · start 2014-01-16

    Registered record
    Registry ID
    NCT02016924
    Conditions
    Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
    Interventions
    ATV; DRV; Cobicistat; BR; F/TAF; LPV/r; Third Unboosted Drug; Cobicistat TOS; F/TAF TOS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2014-01-16
    Completion
    2027-03
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immune Deficiency Syndrome (AIDS); HIV Infections
    InterventionATV; DRV; Cobicistat; BR +5 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

    NCT01929759 · start 2014-01

    Registered record
    Registry ID
    NCT01929759
    Conditions
    HIV Disease
    Interventions
    Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-01
    Completion
    2015-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Disease
    InterventionStribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

    NCT01967940 · start 2013-10-25

    Registered record
    Registry ID
    NCT01967940
    Conditions
    HIV; HIV Infections; Acquired Immunodeficiency Syndrome
    Interventions
    TAF; Placebo; E/C/F/TAF; Current failing ARV regimen; ATV
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-10-25
    Completion
    2017-07-31
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections; Acquired Immunodeficiency Syndrome
    InterventionTAF; Placebo; E/C/F/TAF; Current failing ARV regimen +1 more
    PhasePhase 3
    Registry statusCompleted

  • Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

    NCT01968551 · start 2013-09-03

    Registered record
    Registry ID
    NCT01968551
    Conditions
    HIV-1; HIV Infections; Acquired Immunodeficiency Syndrome
    Interventions
    E/C/F/TAF; DRV; Baseline DRV- containing ARV regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-03
    Completion
    2016-07-09
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1; HIV Infections; Acquired Immunodeficiency Syndrome
    InterventionE/C/F/TAF; DRV; Baseline DRV- containing ARV regimen
    PhasePhase 3
    Registry statusCompleted

  • Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

    NCT01818596 · start 2013-03-27

    Registered record
    Registry ID
    NCT01818596
    Conditions
    HIV; HIV Infections
    Interventions
    E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03-27
    Completion
    2018-07-18
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections
    InterventionE/C/F/TAF
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

    NCT01721109 · start 2012-12-06

    Registered record
    Registry ID
    NCT01721109
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    EVG/COBI/FTC/TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2012-12-06
    Completion
    2018-01-29
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionEVG/COBI/FTC/TDF
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

    NCT01705574 · start 2012-10-24

    Registered record
    Registry ID
    NCT01705574
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    E/C/F/TDF; ATV; RTV; FTC/TDF; E/C/F/TDF Placebo; ATV Placebo; RTV Placebo; FTC/TDF Placebo; E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10-24
    Completion
    2018-09-06
    Enrolment
    583

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionE/C/F/TDF; ATV; RTV; FTC/TDF +5 more
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet

    NCT01694420 · start 2012-09

    Registered record
    Registry ID
    NCT01694420
    Conditions
    HIV
    Interventions
    (FDC) ELV/COBI/FTC/TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09
    Completion
    2017-02
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Intervention(FDC) ELV/COBI/FTC/TDF
    PhasePhase 3
    Registry statusCompleted

  • Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01533259 · start 2012-01

    Registered record
    Registry ID
    NCT01533259
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionStribild
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01495702 · start 2011-12

    Registered record
    Registry ID
    NCT01495702
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    NNRTI; FTC/TDF; Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-12
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionNNRTI; FTC/TDF; Stribild
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

    NCT01328041 · start 2011-05

    Registered record
    Registry ID
    NCT01328041
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2015-05
    Enrolment
    183

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    Interventiondolutegravir
    PhasePhase 3
    Registry statusCompleted

  • Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

    NCT01363011 · start 2011-05

    Registered record
    Registry ID
    NCT01363011
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    E/C/F/TDF; COBI; ATV; DRV; NRTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2015-02
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionE/C/F/TDF; COBI; ATV; DRV +1 more
    PhasePhase 3
    Registry statusCompleted

  • Pilot Study of Raltegravir Lipodystrophy IISP

    NCT01164605 · start 2010-10

    Registered record
    Registry ID
    NCT01164605
    Conditions
    HIV Infection
    Interventions
    Raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-10
    Completion
    2013-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionRaltegravir
    PhaseNot applicable
    Registry statusUnknown

  • Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

    NCT01106586 · start 2010-04

    Registered record
    Registry ID
    NCT01106586
    Conditions
    HIV; HIV Infections
    Interventions
    Stribild; ATV; Ritonavir; FTC/TDF; Stribild Placebo; ATV Placebo; RTV Placebo; FTC/TDF Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    2014-09
    Enrolment
    708

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections
    InterventionStribild; ATV; Ritonavir; FTC/TDF +4 more
    PhasePhase 3
    Registry statusCompleted